Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-22-029906
Filing Date
2022-11-14
Accepted
2022-11-14 17:11:50
Documents
60
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q cpix-20220930.htm   iXBRL 10-Q 1138192
2 EX-10.1 pinnaclebank-cpiamend9tolo.htm EX-10.1 12037
3 EX-31.1 a2022q3-exhibit311.htm EX-31.1 12647
4 EX-31.2 a2022q3-exhibit312.htm EX-31.2 12641
5 EX-32.1 a2022q3-exhibit321.htm EX-32.1 6984
11 image_1.jpg GRAPHIC 32235
12 image_2.jpg GRAPHIC 29543
  Complete submission text file 0001628280-22-029906.txt   4994288

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cpix-20220930.xsd EX-101.SCH 34059
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT cpix-20220930_cal.xml EX-101.CAL 55204
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cpix-20220930_def.xml EX-101.DEF 137444
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cpix-20220930_lab.xml EX-101.LAB 412993
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cpix-20220930_pre.xml EX-101.PRE 272032
54 EXTRACTED XBRL INSTANCE DOCUMENT cpix-20220930_htm.xml XML 707745
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-33637 | Film No.: 221387544
SIC: 2834 Pharmaceutical Preparations